News + Filings Transactions Holdings
|
Rock Springs Capital Management LP
Date | Name | Symbol | Type | Security | Shares | Price | Value | Ownership | Reported |
10/26/2021 | Xilio Therapeutics, Inc. | | Conversion | Series C Preferred Stock | 1.4M | $0.00 | $0 | See footnote | 10/26/2021 |
10/26/2021 | Xilio Therapeutics, Inc. | | Conversion | Common Stock | 756.5k | $0.00 | $0 | See footnote | 10/26/2021 |
10/26/2021 | Xilio Therapeutics, Inc. | | Conversion | Common Stock | 151.3k | $0.00 | $0 | See footnote | 10/26/2021 |
10/26/2021 | Xilio Therapeutics, Inc. | | Purchase | Common Stock | 500k | $16.00 | $8M | See footnote | 10/26/2021 |
10/26/2021 | Xilio Therapeutics, Inc. | | Conversion | Series C Preferred Stock | 7.2M | $0.00 | $0 | See footnote | 10/26/2021 |
10/12/2021 | Theseus Pharmaceuticals, Inc. | THRX | Conversion | Common Stock | 349.3k | $0.00 | $0 | See Footnote | 10/12/2021 |
10/12/2021 | Theseus Pharmaceuticals, Inc. | THRX | Conversion | Common Stock | 87.3k | $0.00 | $0 | See Footnote | 10/12/2021 |
10/12/2021 | Theseus Pharmaceuticals, Inc. | THRX | Purchase | Common Stock | 250k | $16.00 | $4M | See Footnote | 10/12/2021 |
10/12/2021 | Theseus Pharmaceuticals, Inc. | THRX | Conversion | Series B Convertible Preferred Stock | 349.3k | $0.00 | $0 | See Footnote | 10/12/2021 |
10/12/2021 | Theseus Pharmaceuticals, Inc. | THRX | Conversion | Series B Convertible Preferred Stock | 87.3k | $0.00 | $0 | See Footnote | 10/12/2021 |
06/21/2021 | Verve Therapeutics, Inc. | | Conversion | Common Stock | 556.3k | $0.00 | $0 | See Footnote | 06/21/2021 |
06/21/2021 | Verve Therapeutics, Inc. | | Purchase | Common Stock | 370k | $19.00 | $7M | See Footnote | 06/21/2021 |
06/21/2021 | Verve Therapeutics, Inc. | | Conversion | Common Stock | 152.9k | $0.00 | $0 | See Footnote | 06/21/2021 |
06/21/2021 | Verve Therapeutics, Inc. | | Conversion | Series B Preferred Stock | 5.2M | $0.00 | $0 | See Footnote | 06/21/2021 |
06/21/2021 | Verve Therapeutics, Inc. | | Conversion | Series B Preferred Stock | 1.4M | $0.00 | $0 | See Footnote | 06/21/2021 |
11/03/2020 | Atea Pharmaceuticals, Inc. | AVIR | Conversion | Series D-1 Convertible Preferred Stock | 521.7k | $0.00 | $0 | See Footnote | 11/03/2020 |
11/03/2020 | Atea Pharmaceuticals, Inc. | AVIR | Conversion | Series D Convertible Preferred Stock | 178.1k | $0.00 | $0 | See Footnote | 11/03/2020 |
11/03/2020 | Atea Pharmaceuticals, Inc. | AVIR | Conversion | Series D-1 Convertible Preferred Stock | 104.3k | $0.00 | $0 | See Footnote | 11/03/2020 |
11/03/2020 | Atea Pharmaceuticals, Inc. | AVIR | Conversion | Common Stock | 1.4M | $0.00 | $0 | See Footnote | 11/03/2020 |
11/03/2020 | Atea Pharmaceuticals, Inc. | AVIR | Conversion | Common Stock | 282.4k | $0.00 | $0 | See Footnote | 11/03/2020 |
11/03/2020 | Atea Pharmaceuticals, Inc. | AVIR | Purchase | Common Stock | 242.7k | $24.00 | $5.8M | See Footnote | 11/03/2020 |
11/03/2020 | Atea Pharmaceuticals, Inc. | AVIR | Purchase | Common Stock | 7.3k | $24.00 | $175k | See Footnote | 11/03/2020 |
11/03/2020 | Atea Pharmaceuticals, Inc. | AVIR | Conversion | Series D Convertible Preferred Stock | 890.3k | $0.00 | $0 | See Footnote | 11/03/2020 |
07/28/2020 | Inozyme Pharma, Inc. | INZY | Conversion | Common Stock | 467.9k | $0.00 | $0 | See footnote | 07/28/2020 |
07/28/2020 | Inozyme Pharma, Inc. | INZY | Purchase | Common Stock | 576k | $16.00 | $9.2M | See footnote | 07/28/2020 |
07/28/2020 | Inozyme Pharma, Inc. | INZY | Purchase | Common Stock | 24k | $16.00 | $384k | See footnote | 07/28/2020 |
07/28/2020 | Inozyme Pharma, Inc. | INZY | Conversion | Series A-2 Convertible Preferred Stock | 3.5M | $0.00 | $0 | See footnote | 07/28/2020 |
03/16/2020 | Enliven Therapeutics, Inc. | IMRA | Conversion | Common Stock | 273.4k | $0.00 | $0 | See footnote | 03/16/2020 |
03/16/2020 | Enliven Therapeutics, Inc. | IMRA | Purchase | Common Stock | 250k | $16.00 | $4M | See footnote | 03/16/2020 |
03/16/2020 | Enliven Therapeutics, Inc. | IMRA | Conversion | Series B Preferred Stock | 1.7M | $0.00 | $0 | See footnote | 03/16/2020 |
04/02/2018 | Homology Medicines, Inc. | FIXX | Conversion | Common Stock | 395.8k | $0.00 | $0 | See footnote | 04/02/2018 |
04/02/2018 | Homology Medicines, Inc. | FIXX | Purchase | Common Stock | 250k | $16.00 | $4M | See footnote | 04/02/2018 |
04/02/2018 | Homology Medicines, Inc. | FIXX | Conversion | Series B Preferred Stock | 395.8k | $0.00 | $0 | See footnote | 04/02/2018 |
06/22/2015 | ALPINE IMMUNE SCIENCES, INC. | NVLS | Conversion | Common Stock | 364.4k | $0.00 | $0 | By Rock Springs Capital Master Fund LP | 06/22/2015 |
06/22/2015 | ALPINE IMMUNE SCIENCES, INC. | NVLS | Purchase | Common Stock | 200k | $14.00 | $2.8M | By Rock Springs Capital Master Fund LP | 06/22/2015 |
|
|